IMRN: Immuron Ltd Price to Net Income Growth Ratio

Symbol and logo of brand Immuron Limited (IMRN)

The valuation-to-earnings growth ratio for Immuron Limited (IMRN) is based on a loyal customer base and US government contracts for Travelan. The operating model relies on an exclusive B2C health protection brand, while innovation centers on the creation of safe oral antibodies derived from colostrum. The current value is fixed at 0.00, which allows for an assessment of the asset's fundamental attractiveness through the lens of business expansion rates.

Immuron Limited (IMRN): Price/Earnings to Growth Multiple from 07/04/2022 to 11/10/2026

Metric breakdowns and analytics for Immuron Limited (IMRN)

- share price and consensus valuation forecast:
Price Performance Chart immuron.com.au|IMRN - Analyst Consensus Forecast
- market capitalization information:
Market Capitalization Immuron Inc|IMRN - Enterprise Value
- book capitalization data:
Net Assets per Share Immuron|IMRN - Company Net Assets|Market Cap to Book Value Multiple immuron.com.au|IMRN - Company Total Assets
- debt obligations and liquidity statistics:
Total Debt to Capital Coefficient Immuron Limited|IMRN - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio immuron.com.au|IMRN - Company Debts|Debt to Book Value Immuron Inc|IMRN - Company Long-Term Liabilities|Company Short-Term Debts Immuron|Intermediate Coverage Ratio immuron.com.au
- net income and valuation ratios data:
IMRN - Company Net Income|Expected Net Profit Immuron Limited|IMRN - Price to Earnings Ratio|Price to Future Earnings Ratio immuron.com.au|IMRN - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation Immuron Inc|IMRN - Profit before payment of interest, taxes and amortization|Earnings per share for the last twelve months Immuron|IMRN - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months immuron.com.au|IMRN - Earnings per share growth in current year|Expected earnings per share growth for next year Immuron Limited
Fundamental company analysis:IMRN (Immuron Ltd)
Core merchandise of Immuron

The metric is calculated by dividing the P/E ratio by the company's earnings growth rate. A value below one indicates a fundamental undervaluation of the asset relative to its expansion. For Immuron Limited (IMRN), the limited market size for colostrum-based products constrains aggressive revenue growth. Analysis of the PEG ratio chart helps determine whether the scaling potential offsets the current share price.

Who Immuron Limited competes with

PHAT (Phathom Pharma) - Growth-Adjusted Payback Ratio|PEG Multiple TERN (Terns Pharmaceuticals Inc)|Price to Net Income Growth Ratio Ironwood Pharma|Curanex - PEG Multiple|Growth-Adjusted Market Cap to Net Income evokepharma.com EVOK|ENTO (enterothera.com) - Price/Earnings to Growth Multiple|RDHL: Company Value to Earnings Growth Ratio|PALI (Palisade Bio, Inc.) - PEG Multiple|Jaguar Health Corp (JAGX) - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio Biora Therapeutics (BIOR)|Price/Earnings to Growth Multiple morphictx.com MORF